Aesthetics is looking past wrinkles toward biology. March congress data spotlighted collagen-stimulating biostimulators and a growing focus on menopause-related skin change, reframing injectables as part of long-term skin health.
March 2026 congress data widened the aesthetic lens in two directions: regenerative biostimulators such as poly-L-lactic acid that prompt the body to build collagen, and a growing focus on menopause-related skin change, where hormonal shifts affect skin quality. Together they frame injectables as part of long-term skin health, not just wrinkle correction.
Two related themes ran through the March congress season: regeneration and a more honest reckoning with how skin ages, including at menopause.
Both point to aesthetics broadening beyond surface lines toward underlying skin biology.
Congress posters addressed the regenerative effects of poly-L-lactic acid (PLLA), a biostimulator that stimulates the body own collagen over time, including consensus work on its use for non-facial rejuvenation. Separately, data explored the role of biostimulators and fillers in addressing menopause-related skin conditions, acknowledging that hormonal changes around menopause can accelerate collagen loss, dryness, and laxity. A multi-country survey presented earlier in the season had also examined how menopause affects the skin.
The combined message is that aesthetics is increasingly engaging with skin biology and life stages, not just static wrinkles. Regenerative approaches aim to improve skin quality and structure gradually, and menopause is being recognized as a meaningful, under-discussed driver of skin change worth addressing thoughtfully.
For consumers, this reframing is useful and humane: it treats skin change as a biological process to support rather than a flaw to erase, and it validates seeking care around menopause. But regenerative and hormone-adjacent marketing also invites overreach. Biostimulators build results gradually and require experienced injectors, and skin care around menopause is best handled with realistic expectations and, where relevant, coordination with broader medical care.
Watch for more rigorous data on biostimulators for specific areas and populations, and for menopause-focused aesthetic care becoming a clearer category rather than a marketing label. For patients, the grounding questions are what evidence supports a regenerative treatment for their goal, how many sessions it requires, and whether menopause-related skin concerns might also warrant input from their broader healthcare team alongside aesthetic options.